
Editas Medicine Inc
NASDAQ:EDIT

ROCE
Return on Capital Employed
ROCE, or Return on Capital Employed, is a financial ratio that measures a company’s profitability in relation to the capital it employs.
ROCE Across Competitors
Country | Company | Market Cap | ROCE | ||
---|---|---|---|---|---|
US |
![]() |
Editas Medicine Inc
NASDAQ:EDIT
|
164.9m USD |
-73%
|
|
FR |
![]() |
Pharnext SCA
OTC:PNEXF
|
6T USD |
275%
|
|
US |
![]() |
Abbvie Inc
NYSE:ABBV
|
337.5B USD |
17%
|
|
US |
![]() |
Amgen Inc
NASDAQ:AMGN
|
158.7B USD |
12%
|
|
US |
![]() |
Gilead Sciences Inc
NASDAQ:GILD
|
136.9B USD |
25%
|
|
US |
![]() |
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
117B USD |
21%
|
|
US |
E
|
Epizyme Inc
F:EPE
|
94.1B EUR |
-73%
|
|
AU |
![]() |
CSL Ltd
ASX:CSL
|
116.1B AUD |
12%
|
|
US |
![]() |
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
57.3B USD |
13%
|
|
US |
S
|
Seagen Inc
F:SGT
|
39.3B EUR |
-27%
|
|
US |
![]() |
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
|
40.1B USD |
-4%
|
Editas Medicine Inc
Glance View
Editas Medicine, Inc. engages in the development and commercialization of genome editing technology. The company is headquartered in Cambridge, Massachusetts and currently employs 264 full-time employees. The company went IPO on 2016-02-03. The firm is focused on developing transformative gene editing medicines to treat a range of serious diseases. The company has developed a gene editing platform based on clustered, regularly interspaced short palindromic repeats (CRISPR) technology. CRISPR uses a protein-ribonucleic acid (RNA) complex composed of an enzyme, including either CRISPR associated protein 9 (Cas9) or CRISPR from Prevotella and Francisella 1 (Cpf1), bound to a guide RNA molecule designed to recognize a particular deoxyribonucleic acid (DNA) sequence. The firm is focused on both in vivo gene editing medicines, in which the medicine is injected or infused into the patient to edit the cells inside their body, and ex vivo gene-edited cell medicines, in which cells are edited with its technology. The firm's gene editing medicine programs include EDIT-101, EDIT-102, EDIT-103, EDIT-301 and EDIT-202.

See Also
ROCE, or Return on Capital Employed, is a financial ratio that measures a company’s profitability in relation to the capital it employs.
Based on Editas Medicine Inc's most recent financial statements, the company has ROCE of -73.4%.